Research programme: anti-IL-2 monoclonal antibodies - Aulos Bioscience
Latest Information Update: 05 Feb 2021
At a glance
- Originator Biolojic Design
- Developer Aulos Bioscience
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Regulatory T-lymphocyte inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours